PIII Stock Overview
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States.
P3 Health Partners Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.07|
|52 Week High||US$16.73|
|52 Week Low||US$3.41|
|1 Month Change||-1.36%|
|3 Month Change||31.69%|
|1 Year Change||-48.74%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-47.63%|
Recent News & Updates
P3 Health gets Nasdaq notice for delisting, plans appeal
P3 Health Partners (NASDAQ:PIII) said that Nasdaq has started a process which could result in the delisting of the company’s securities from the exchange. The company intends to appeal the Staff Determination before a Nasdaq Hearing Panel and seek a further stay of any suspension or delisting action pending the hearing process, P3 said in an Oct. 4 press release. P3 noted that the request for a hearing must be made by Oct. 5. The Staff Determination was issued because the company has not filed its annual report on Form 10-K for the fiscal year ended Dec. 31, 2021 or its quarterly reports on Form 10-Q for March 31, and June 30.
P3 Health expands Nevada footprint with acquisition of Pahrump cardiology practice
P3 Health Partners (NASDAQ:PIII) said Monday its unit P3 Health Partners-Nevada acquired Pahrump Cardiology & Family Practice, expanding its footprint in Nye County, Nevada. The cardiology and multi-specialty practice joins PIII's existing clinic in Pahrump.
|PIII||US Healthcare||US Market|
Return vs Industry: PIII underperformed the US Healthcare industry which returned 13.9% over the past year.
Return vs Market: PIII underperformed the US Market which returned -18.8% over the past year.
|PIII Average Weekly Movement||9.6%|
|Healthcare Industry Average Movement||7.7%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: PIII is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: PIII's weekly volatility (10%) has been stable over the past year.
About the Company
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company is based in Henderson, Nevada.
P3 Health Partners Fundamentals Summary
|PIII fundamental statistics|
Is PIII overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PIII income statement (TTM)|
|Cost of Revenue||US$596.49m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.19|
|Net Profit Margin||-15.58%|
How did PIII perform over the long term?See historical performance and comparison
Is PIII undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PIII?
Other financial metrics that can be useful for relative valuation.
|What is PIII's n/a Ratio?|
Price to Sales Ratio vs Peers
How does PIII's PS Ratio compare to its peers?
|PIII PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
FLGT Fulgent Genetics
HIMS Hims & Hers Health
CCRN Cross Country Healthcare
PIII P3 Health Partners
Price-To-Sales vs Peers: PIII is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (1.4x).
Price to Earnings Ratio vs Industry
How does PIII's PE Ratio compare vs other companies in the US Healthcare Industry?
Price-To-Sales vs Industry: PIII is good value based on its Price-To-Sales Ratio (0.4x) compared to the US Healthcare industry average (1.3x)
Price to Sales Ratio vs Fair Ratio
What is PIII's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.4x|
|Fair PS Ratio||2.7x|
Price-To-Sales vs Fair Ratio: PIII is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (2.7x).
Share Price vs Fair Value
What is the Fair Price of PIII when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate PIII's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PIII's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
- Take a look at our analysis of PIII's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
How is P3 Health Partners forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if PIII's forecast earnings growth is above the savings rate (1.9%).
Earnings vs Market: Insufficient data to determine if PIII's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if PIII's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PIII's revenue (42.3% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: PIII's revenue (42.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PIII's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has P3 Health Partners performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: PIII is currently unprofitable.
Growing Profit Margin: PIII is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PIII's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PIII's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PIII is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (1.9%).
Return on Equity
High ROE: PIII's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
How is P3 Health Partners's financial position?
Financial Health Score0/6
Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: PIII has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: PIII has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: PIII has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: PIII's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if PIII has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PIII has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is P3 Health Partners's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|P3 Health Partners Dividend Yield vs Market|
|Company (P3 Health Partners)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Healthcare)||1.4%|
|Analyst forecast in 3 Years (P3 Health Partners)||n/a|
Notable Dividend: Unable to evaluate PIII's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PIII's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PIII's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PIII's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PIII has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sherif Abdou (62 yo)
Dr. Sherif Abdou, MD, MMM, FACP, FACPE is CEO & Director at P3 Health Partners Inc. He has focused his 30-year career on managing and leading the transformation of the health care delivery system throughou...
CEO Compensation Analysis
|Sherif Abdou's Compensation vs P3 Health Partners Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$1m||US$743k|
Compensation vs Market: Insufficient data to establish whether Sherif's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Insufficient data to compare Sherif's compensation with company performance.
Experienced Management: PIII's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: PIII's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|28 Jan 22||BuyUS$72,450||Michael Balkin||Individual||15,000||US$4.83|
|19 Jan 22||BuyUS$21,619||Michael Balkin||Individual||4,239||US$5.10|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 503.5%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
P3 Health Partners Inc.'s employee growth, exchange listings and data sources
- Name: P3 Health Partners Inc.
- Ticker: PIII
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: US$1.213b
- Market Cap: US$210.805m
- Shares outstanding: 243.60m
- Website: https://p3hp.org
Number of Employees
- P3 Health Partners Inc.
- 2370 Corporate Circle
- Suite 300
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PIII||NasdaqCM (Nasdaq Capital Market)||Yes||Class A Common Stock||US||USD||Apr 2021|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/06 00:00|
|End of Day Share Price||2022/10/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.